IKEA Supply AG et al. v. Everlight Electronics Co., Ltd.

IPR2024-00987

IKEA Supply AG and Everlight Electronics jointly filed a motion to have their settlement agreement treated as business confidential information under 35 U.S.C. §317(b) in IPR2024-00987.

Jurisdiction
US PTAB
Case Number
IPR2024-00987
Decision Date
31 May 2024
Filing Date
31 May 2024

Detailed Summary

In IPR2024-00987 concerning U.S. Patent No. 9,905,742, petitioner IKEA Supply AG and patent owner Everlight Electronics Co., Ltd. submitted a joint request to the PTAB to treat their settlement agreement as business confidential information. Citing 35 U.S.C. §317(b) and relevant CFR provisions, they argue the agreement contains confidential terms that resolve their dispute and should be kept separate from the patent file. The request was filed concurrently with the agreement, satisfying the Board’s timeliness requirements, and seeks the Board’s approval for confidential treatment.

Practitioner Note

This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in IKEA Supply AG et al. vs Everlight Electronics Co., Ltd. is valuable context for structuring arguments or assessing risk in similar proceedings.

Related Cases

patentIPR2024-01224

LENOVO (UNITED STATES) INC. et al.vsIntellectual Ventures I LLC

Lenovo’s request for director review of the PTAB’s decision on its IPR challenging patent 7,623,439 was denied. The Board found the petitioner introduced new arguments and evidence not previously presented and failed to show good cause for submitting additional evidence.

patentIPR2025-00631

Revvo Technologies, Inc.vsTire Stickers LLC et al.

Revvo Technologies files a response opposing Tire Stickers’ untimely Director Review request, arguing the Board has already institutioned the IPR and found no claim construction needed.

patentIPR2025-00946

AZURITY PHARMACEUTICALS, INC.vsHelsinn Healthcare S.A.

Azurity has filed an IPR petition seeking cancellation of 23 claims of Helsinn’s anti‑emetic patent covering netupitant, palonosetron and dexamethasone regimens. The challenger alleges obviousness over multiple prior‑art references and disputes the asserted unexpected synergy. No decision has been issued yet.

patentPGR2025-00023

Charles River Laboratories, Inc.vsSeikagaku Corporation

Charles River Laboratories successfully petitioned to invalidate Seikagaku Corporation's patent claims related to endotoxin detection. The Board found grounds for invalidity under 35 U.S.C. § 102 and § 112, specifically citing anticipation by a prior publication.

patentIPR2026-00098

Google LLCvsSecure Communication Technologies, LLC

The PTAB held that all challenged claims of the ’359 patent are unpatentable, finding anticipation or obviousness over Perttila and, for certain claims, over the Perttila‑Swartz combination. The decision resolves the IPR filed by Google against Secure Communication Technologies.

Arctic Invent — IP Strategy

Dealing with a patent challenge?

Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.

Talk to our patent team →

Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.

Strategy Consult

Facing a similar patent matter?

Arctic's litigation team uses precedent data like this to build winning arguments.

Get a Strategy Call